Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05599048 | Hyperpolarized 13C MRI as a Biomarker in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 65 | Robert Bok, MD, PhDOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04381806 | Phase I Study in Advanced Malignancies With 5-ALA | suspended | Phase 1 | 130 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05277168 |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS |
| recruiting |
| Phase 1 / Phase 2 |
| 83 |
| Jiangsu HengRui Medicine Co., Ltd.INDUSTRY |
| 4 |
| May 22, 2026 |
| clinicaltrials |
| NCT05839600 | A Study to Find a Suitable Dose of BI 1821736 and Test Whether it Helps People With Advanced Cancer | terminated | Phase 1 | 10 | Boehringer IngelheimINDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT06386146 | JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | recruiting | Phase 1 / Phase 2 | 144 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT06656390 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 202 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT06977737 | A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours(ATTEST) | recruiting | Phase 1 / Phase 2 | 72 | Accession Therapeutics LimitedINDUSTRY | 2 | May 22, 2026 | clinicaltrials |
| NCT02321501 | Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | active not recruiting | Phase 1 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04388852 | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers | active not recruiting | Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06006273 | A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors | recruiting | Phase 1 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04897321 | B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | recruiting | Phase 1 | 48 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04901702 | Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | recruiting | Phase 1 / Phase 2 | 90 | St. Jude Children's Research HospitalOTHER | 2 | May 19, 2026 | clinicaltrials |
| NCT05468359 | Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 64 | St. Jude Children's Research HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07596381 | FAK Inhibitor in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 75 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT07596693 | KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma) | recruiting | Phase 1 | 30 | TCRx Therapeutics Co.LtdINDUSTRY | 1 | May 19, 2026 | clinicaltrials |
| NCT05678010 | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer | active not recruiting | Phase 1 | 54 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT06724926 | Concurrent Azeliragon With Craniospinal Irradiation | active not recruiting | Phase 1 | 21 | NYU Langone HealthOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07094204 | A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors | recruiting | Phase 1 | 364 | Astellas Pharma IncINDUSTRY | 4 | May 18, 2026 | clinicaltrials |
| NCT07459998 | SKB103 for Injection in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 277 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 18, 2026 | clinicaltrials |
| NCT07594028 | Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours | not yet recruiting | Phase 1 / Phase 2 | 126 | Sinocelltech Ltd.INDUSTRY | 0 | May 18, 2026 | clinicaltrials |
| NCT02444741 | Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 124 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT05173142 | A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 190 | Hutchison Medipharma LimitedINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05329103 | A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 65 | Peel Therapeutics IncINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | recruiting | Phase 1 / Phase 2 | 754 | Revolution Medicines, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | active not recruiting | Phase 1 | 222 | Revolution Medicines, Inc.INDUSTRY | 13 | May 15, 2026 | clinicaltrials |
| NCT06066424 | Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA) | recruiting | Phase 1 | 54 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT07589530 | Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors(SOLID-NK) | recruiting | Phase 1 / Phase 2 | 60 | Beijing BiotechINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT07591285 | A Study of SYS6051 in Subjects With Advanced Solid Tumors | not yet recruiting | Phase 1 | 114 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | May 15, 2026 | clinicaltrials |
| NCT03735095 | Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer | completed | Phase 1 / Phase 2 | 19 | Roswell Park Cancer InstituteOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06739291 | A Study of SIGX1094R in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 102 | Signet TherapeuticsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT07587879 | Novel mRNA-LNP-Based Intratumoral Immunotherapy in Patients With Advanced Malignant Solid Tumors(mRNA-LNP) | not yet recruiting | Phase 1 / Phase 2 | 60 | IntraAb, Inc.INDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT02797795 | A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers | completed | Phase 1 | 78 | Neovia Oncology Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT03686124 | ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors(ACTengine) | recruiting | Phase 1 / Phase 2 | 375 | Immatics US, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | completed | Phase 1 / Phase 2 | 225 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05036226 | COAST Therapy in Advanced Solid Tumors and Prostate Cancer(COAST) | recruiting | Phase 1 / Phase 2 | 76 | Medical University of South CarolinaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT06223542 | Studying TAK-243 in Patients With Advanced Cancer | recruiting | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07582822 | JH021 in Patients With Advanced Solid Tumors or EGFR-Mutant NSCLC | not yet recruiting | Phase 1 | 60 | Biotech Pharmaceutical Co., Ltd.OTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583771 | A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma | not yet recruiting | Phase 1 | 186 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05038839 | Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors | completed | Phase 1 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT05162755 | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers | completed | Phase 1 | 41 | Institut de Recherches Internationales ServierOTHER | 2 | May 12, 2026 | clinicaltrials |
| NCT05438329 | First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 1,123 | DualityBio Inc.INDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT05582850 | DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours(EPRAD) | terminated | Phase 1 | 29 | Domain Therapeutics SAINDUSTRY | 2 | May 12, 2026 | clinicaltrials |
| NCT04502602 | Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer(iNNOVATE) | active not recruiting | Phase 1 | 18 | Virginia Commonwealth UniversityOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05076396 | PM14 Administered Intravenously to Patients With Advanced Solid Tumors | completed | Phase 1 | 126 | PharmaMarINDUSTRY | 3 | May 11, 2026 | clinicaltrials |
| NCT06474455 | A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 156 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT06487858 | A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors | terminated | Phase 1 | 42 | BeOne MedicinesINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT07563972 | Intratumoral Macrophage Exosomes With Mechanobiological Reprogramming for Advanced Solid Tumors | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05265091 | A Study of KL590586 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 414 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 27, 2026source: clinicaltrials